ELYSON PHARM has a total of 11 patent applications. It increased the IP activity by 300.0%. Its first patent ever was published in 2016. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals are JILIN YIZHENG PHARMACEUTICAL GROUP CO LTD, DENGFENG TONGDA SCIENCE & TECH CO LTD and WANG LIUSHENG.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Australia | 1 | |
#4 | Canada | 1 | |
#5 | China | 1 | |
#6 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Dhong Eul Won | 9 |
#2 | Kim Hae Yang | 7 |
#3 | Hu Hong Gu | 5 |
#4 | Shin Hye-Gyeong | 4 |
#5 | Park Sang-Geun | 4 |
#6 | Park Hyo-Jin | 4 |
#7 | Lim Sun Joo | 3 |
#8 | Heo Hong Gu | 2 |
#9 | Sagn- Geun Park | 1 |
#10 | Hong Gu Hu | 1 |
Publication | Filing date | Title |
---|---|---|
WO2019022436A2 | Pharmaceutical composition comprising nep inhibitor and beta-blocker | |
KR20190013509A | Pharmaceutical composition comprising nep inhibitors and beta-blocker | |
KR20190107838A | Sustained-release pharmaceutical composition of ivabradine and process for preparing the same | |
KR20190001340A | Sustained-release pharmaceutical composition comprising ivabradine and process for preparing the same | |
WO2017119629A1 | Pharmaceutical composition comprising nebivolol with improved dissolution rate | |
KR20170083484A | Pharmaceutical composition with improved dissolution rate comprising nebivolol |